North Star Investment Management Corp. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 20.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 203,108 shares of the biopharmaceutical company’s stock after purchasing an additional 34,701 shares during the period. Pfizer accounts for approximately 0.9% of North Star Investment Management Corp.’s portfolio, making the stock its 24th biggest position. North Star Investment Management Corp.’s holdings in Pfizer were worth $7,454,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NewSquare Capital LLC grew its position in shares of Pfizer by 0.4% in the second quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock valued at $1,976,000 after purchasing an additional 266 shares during the last quarter. Aevitas Wealth Management Inc. lifted its holdings in shares of Pfizer by 1.7% during the second quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock worth $520,000 after buying an additional 269 shares during the last quarter. Cutter & CO Brokerage Inc. grew its stake in shares of Pfizer by 2.0% in the second quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 274 shares during the last quarter. Beaumont Asset Management L.L.C. increased its position in Pfizer by 1.3% during the second quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock worth $694,000 after acquiring an additional 276 shares during the period. Finally, Dividend Assets Capital LLC raised its stake in Pfizer by 0.9% during the 2nd quarter. Dividend Assets Capital LLC now owns 30,606 shares of the biopharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 278 shares during the last quarter. Hedge funds and other institutional investors own 69.08% of the company’s stock.

PFE opened at $37.95 on Friday. The firm has a market cap of $210.88 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 2.91 and a beta of 0.67. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The firm’s 50-day simple moving average is $36.59 and its 200-day simple moving average is $36.32. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The firm had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. During the same period in the previous year, the business earned $0.80 earnings per share. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a $0.38 dividend. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. Pfizer’s dividend payout ratio is 51.53%.

PFE has been the topic of several research reports. Royal Bank of Canada set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Friday. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and cut their price target for the company from $44.00 to $39.00 in a report on Monday, October 12th. Morgan Stanley raised their price objective on Pfizer from $36.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. UBS Group boosted their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Finally, Piper Sandler raised their target price on Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $39.64.

In related news, Director Ronald E. Blaylock acquired 13,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, with a total value of $501,150.00. Following the acquisition, the director now directly owns 4,000 shares in the company, valued at $154,200. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.08% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Learning About the VIX – Volatility Index

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.